Shanghai Henlius Biotech, Inc. (HKG: 2696)

Market Cap	12.88B
Revenue (ttm)	6.06B
Net Income (ttm)	743.92M
Shares Out	543.49M
EPS (ttm)	1.36
PE Ratio	17.37
Forward PE	20.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,600
Open	23.85
Previous Close	23.90
Day's Range	23.85 - 23.95
52-Week Range	12.20 - 23.95
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 23, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,637
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

Financial numbers in CNY